Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 204

Sort by

Sort Order Select

Journal Articles

Reduction in MPN-Total Symptom Score (TSS) Is Associated with Overall Survival (OS) in Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, Wenyi Fan, Sara M. Tinsley-Vance, Amy E. DeZern, Hetty E. Carraway, Marlise R. Luskin, Gail J. Roboz, Onyee Chan, Aaron T. Gerds, Andrew T. Kuykendall, David P. Steensma, Maria Balasis, Jeffrey E Lancet, Qianxing Mo, Mikkael A. Sekeres, David Sallman, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 6750.

https://doi.org/10.1182/blood-2024-211137

Published: 2024

Journal Articles

A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

John O. Mascarenhas, Uma Borate, Prithviraj Bose, John C. Byrd, Jacqueline S. Garcia, Michael R. Grunwald, Gabriela S. Hobbs, Ronald Hoffman, Andrew T. Kuykendall, Ruben A. Mesa, Stephen Oh, Raajit Rampal, Abdulraheem Yacoub, David P. Steensma

Blood (2024) 144 (Supplement 1): 3147.1.

https://doi.org/10.1182/blood-2024-193905

Published: 2024

Journal Articles

Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenström Macroglobulinemia

Sabrin Tahri, Tarek H Mouhieddine, Robert A. Redd, Luisa Maria Lampe, Katarina Nillson, Nang Kham Su, Habib El-Khoury, Amin H Nassar, Elio Adib, Govind Bindra, Sarah Abou Alaiwi, Lorenzo Trippa, David P. Steensma, Jorge J. Castillo, Steven P. Treon, Irene M. Ghobrial, Adam S. Sperling

Blood (2021) 138 (Supplement 1): 2678.

https://doi.org/10.1182/blood-2021-149711

Published: 2021

Journal Articles

Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients

Tarek H. Mouhieddine, Chidimma Nzerem, Robert A. Redd, Andrew Dunford, Matthew Joseph Leventhal, Romanos Sklavenitis-Pistofidis, Sabrin Tahri, Habib El-Khoury, David P. Steensma, Benjamin L. Ebert, Robert J. Soiffer, Jonathan J Keats, Shaadi Mehr, Daniel Auclair, Adam S. Sperling, Chip Stewart, Gad Getz, Irene M. Ghobrial

Blood (2021) 138 (Supplement 1): 1091.

https://doi.org/10.1182/blood-2021-152025

Published: 2021

Journal Articles

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 246.

https://doi.org/10.1182/blood-2021-153286

Published: 2021

Journal Articles

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome

Mikko Myllymäki, Robert Redd, Christopher R. Reilly, Wael Saber, Stephen R. Spellman, Christopher J. Gibson, Zhen-Huan Hu, Tao Wang, Esther H. Orr, Jaclyn G. Grenier, Maxine M. Chen, David P. Steensma, Corey Cutler, Immaculata De Vivo, Joseph H. Antin, Donna Neuberg, Suneet Agarwal, R. Coleman Lindsley

Blood (2020) 136 (26): 3070–3081.

https://doi.org/10.1182/blood.2020005397

Published: 2020

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-136235

Published: 2020

Journal Articles

A Critical Role for Patient Education in Improving Patient-Provider Communication and Treatment Decisions across Rare Hematologic Malignancies

Tariqa A Ackbarali, PhDc), Robert J. Kreitman, MD, David P. Steensma, MD, Steven M. Horwitz, MD, Wendy Turell, Kathryn Pucci, MBA

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-141646

Published: 2020

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134947

Published: 2020

Journal Articles

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

Niroshan Nadarajah, Alex Wagner, PhD, Rafael Bejar, MD PhD, Mark Ewalt, MD, Annette S. Kim, MD, Michelle M. Le Beau, PhD, Xiaotu Ma, PhD, Manja Meggendorfer, PhD, Jamile M. Shammo, MD, Gabriella Ryan, Alexa J. Siddon, MD, David P. Steensma, MD, Matthew J. Walter, MD, Ahmet Zehir, PhD, Jinghui Zhang, PhD, Torsten Haferlach, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141204

Published: 2020

Journal Articles

What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics

David P. Steensma, Kelly L. Bolton

Blood (2020) 136 (14): 1623–1631.

https://doi.org/10.1182/blood.2019004291

Published: 2020

Includes: Supplemental data

Journal Articles

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia-Manero, Elizabeth A. Griffiths, David P. Steensma, Gail J. Roboz, Richard Wells, James McCloskey, II, Olatoyosi Odenike, Amy E. DeZern, Karen Yee, Lambert Busque, Casey O’Connell, Laura C. Michaelis, Joseph Brandwein, Hagop Kantarjian, Aram Oganesian, Mohammad Azab, Michael R. Savona

Blood (2020) 136 (6): 674–683.

https://doi.org/10.1182/blood.2019004143

Published: 2020

Journal Articles

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Blood (2020) 136 (2): 157–170.

https://doi.org/10.1182/blood.2020004850

Published: 2020

Journal Articles

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

Robert P. Hasserjian, David P. Steensma, Timothy A. Graubert, Benjamin L. Ebert

Blood (2020) 135 (20): 1729–1738.

https://doi.org/10.1182/blood.2019004770

Published: 2020

Journal Articles

Does clonal hematopoiesis explain unexplained anemia?

David P. Steensma

Blood (2020) 135 (14): 1080–1082.

https://doi.org/10.1182/blood.2020005293

Published: 2020

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 676.

https://doi.org/10.1182/blood-2019-131055

Published: 2019

Journal Articles

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 1715.

https://doi.org/10.1182/blood-2019-129141

Published: 2019

NARROW

Reduction in MPN-Total Symptom Score (TSS) Is Associated with Overall Survival (OS) in Chronic Myelomonocytic Leukemia (CMML)

Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenström Macroglobulinemia

Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

A Critical Role for Patient Education in Improving Patient-Provider Communication and Treatment Decisions across Rare Hematologic Malignancies

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

Does clonal hematopoiesis explain unexplained anemia?

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only